This baseline local immune control contributes to improved patient survival in MSI-H CRC and also sensitizes tumors in these patients to immune checkpoint inhibitors targeting either programmed cell death-1 protein (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Here, CTLA4 is linked to colorectal carcinoma.